Literature DB >> 9632668

The C-terminal region of the factor V B-domain is crucial for the anticoagulant activity of factor V.

E Thorelli1, R J Kaufman, B Dahlbäck.   

Abstract

Factor V (FV) is recently shown to express anticoagulant activity. It functions as a synergistic cofactor with protein S to activated protein C (APC) in the degradation of factor VIIIa (FVIIIa). FV is composed of multiple domains, A1-A2-B-A3-C1-C2. Thrombin cleaves FV at Arg-709, Arg-1018, and Arg-1545 that leads to the generation of a procoagulant FV species which functions as a cofactor to factor Xa (FXa) in the activation of prothrombin to thrombin. During the activation process, the B-domain is released from the heavy (A1-A2) and light chains (A3-C1-C2) which constitute the active FV (FVa). To elucidate which effect the different thrombin cleavages in FV have on the ability of FV to express APC-cofactor activity, seven recombinant FV mutants containing all possible combinations of mutated and native thrombin cleavage sites were tested in a FVIIIa degradation assay. Thrombin cleavage at Arg-709 and/or Arg-1018 yielded FV molecules that were still able to function as APC cofactors, whereas cleavage at Arg-1545 led to a complete loss in APC-cofactor function. This suggests that the APC-cofactor function of FV depends on the B-domain remaining attached to the A3 domain. The importance of the FV B-domain for expression of APC-cofactor activity was further investigated using two B-domain deleted FV molecules, FV des-709-1545 (with the whole B-domain deleted) and FV des-709-1476 (with amino acids 710-1476 of the B-domain being removed). FV des-709-1476 expressed APC-cofactor activity, whereas the FV des-709-1545 was completely devoid of such activity. Thus, the C-terminal part of the B-domain (residues 1477-1545) was crucial for the APC-cofactor function. FV and factor VIII (FVIII) are homologous proteins having similar domain organization. A FV/FVIII chimera, harboring the B-domain from FVIII (FVBVIII) instead of the FV B-domain did not work as an APC cofactor, further illustrating the importance of the FV B-domain for the APC-cofactor function.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9632668     DOI: 10.1074/jbc.273.26.16140

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  9 in total

1.  Factor V is an anticoagulant cofactor for activated protein C during inactivation of factor Va.

Authors:  Thomas J Cramer; John H Griffin; Andrew J Gale
Journal:  Pathophysiol Haemost Thromb       Date:  2010-05-22

2.  APCR, factor V gene known and novel SNPs and adverse pregnancy outcomes in an Irish cohort of pregnant women.

Authors:  Sara Sedano-Balbás; Mark Lyons; Brendan Cleary; Margaret Murray; Geraldine Gaffney; Majella Maher
Journal:  BMC Pregnancy Childbirth       Date:  2010-03-10       Impact factor: 3.007

Review 3.  Progress in the understanding of the protein C anticoagulant pathway.

Authors:  Björn Dahlbäck
Journal:  Int J Hematol       Date:  2004-02       Impact factor: 2.490

4.  Coagulation factor V mediates inhibition of tissue factor signaling by activated protein C in mice.

Authors:  Hai Po H Liang; Edward J Kerschen; Sreemanti Basu; Irene Hernandez; Mark Zogg; Shuang Jia; Martin J Hessner; Raffaella Toso; Alireza R Rezaie; José A Fernández; Rodney M Camire; Wolfram Ruf; John H Griffin; Hartmut Weiler
Journal:  Blood       Date:  2015-09-04       Impact factor: 22.113

5.  Factor V has an anticoagulant cofactor activity that targets the early phase of coagulation.

Authors:  Salvatore Santamaria; Natalia Reglińska-Matveyev; Magdalena Gierula; Rodney M Camire; James T B Crawley; David A Lane; Josefin Ahnström
Journal:  J Biol Chem       Date:  2017-04-18       Impact factor: 5.157

6.  Minor allele of the factor V K858R variant protects from venous thrombosis only in non-carriers of factor V Leiden mutation.

Authors:  M Ibrahim-Kosta; P Suchon; F Couturaud; D Smadja; R Olaso; M Germain; N Saut; L Goumidi; C Derbois; F Thibord; S Debette; P Amouyel; J F Deleuze; P van Doorn; E Castoldi; E Patin; M C Alessi; D A Trégouët; P E Morange
Journal:  Sci Rep       Date:  2019-03-06       Impact factor: 4.379

7.  The roles of factor Va and protein S in formation of the activated protein C/protein S/factor Va inactivation complex.

Authors:  Magdalena Gierula; Isabelle I Salles-Crawley; Salvatore Santamaria; Adrienn Teraz-Orosz; James T B Crawley; David A Lane; Josefin Ahnström
Journal:  J Thromb Haemost       Date:  2019-08-09       Impact factor: 5.824

8.  Coagulation factor V is a T-cell inhibitor expressed by leukocytes in COVID-19.

Authors:  Jun Wang; Prasanti Kotagiri; Paul A Lyons; Rafia S Al-Lamki; Federica Mescia; Laura Bergamaschi; Lorinda Turner; Michael D Morgan; Fernando J Calero-Nieto; Karsten Bach; Nicole Mende; Nicola K Wilson; Emily R Watts; Patrick H Maxwell; Patrick F Chinnery; Nathalie Kingston; Sofia Papadia; Kathleen E Stirrups; Neil Walker; Ravindra K Gupta; David K Menon; Kieren Allinson; Sarah J Aitken; Mark Toshner; Michael P Weekes; James A Nathan; Sarah R Walmsley; Willem H Ouwehand; Mary Kasanicki; Berthold Göttgens; John C Marioni; Kenneth G C Smith; Jordan S Pober; John R Bradley
Journal:  iScience       Date:  2022-02-22

9.  A hydrophobic patch (PLVIVG; 1481-1486) in the B-domain of factor V-short is crucial for its synergistic TFPIα-cofactor activity with protein S and for the formation of the FXa-inhibitory complex comprising FV-short, TFPIα, and protein S.

Authors:  Björn Dahlbäck; Sinh Tran
Journal:  J Thromb Haemost       Date:  2022-03-16       Impact factor: 16.036

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.